Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) Receives Average Rating of “Hold” from Brokerages

Shares of Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) have earned a consensus rating of “Hold” from the fifteen research firms that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, twelve have assigned a hold recommendation and two have issued a buy recommendation on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $109.00.

Several equities analysts have weighed in on the company. Roth Capital cut Verona Pharma PLC American Depositary Share from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 10th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $100.00 price objective on shares of Verona Pharma PLC American Depositary Share in a research report on Wednesday, October 8th. Wolfe Research lowered shares of Verona Pharma PLC American Depositary Share from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 10th. BTIG Research lowered shares of Verona Pharma PLC American Depositary Share from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 10th. Finally, Wells Fargo & Company cut shares of Verona Pharma PLC American Depositary Share from a “strong-buy” rating to a “hold” rating and lowered their price target for the company from $138.00 to $107.00 in a report on Thursday, July 10th.

Verona Pharma PLC American Depositary Share Price Performance

Shares of NASDAQ:VRNA opened at $106.91 on Friday. The company’s fifty day moving average is $106.63 and its two-hundred day moving average is $95.69. The company has a market cap of $9.21 billion, a P/E ratio of -107.99 and a beta of 0.05. Verona Pharma PLC American Depositary Share has a 12-month low of $31.09 and a 12-month high of $106.93. The company has a quick ratio of 10.54, a current ratio of 10.71 and a debt-to-equity ratio of 0.87.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) last issued its earnings results on Wednesday, August 6th. The company reported $0.13 EPS for the quarter, topping the consensus estimate of ($0.01) by $0.14. The business had revenue of $103.14 million during the quarter, compared to analysts’ expectations of $90.41 million. Verona Pharma PLC American Depositary Share had a negative return on equity of 21.12% and a negative net margin of 36.62%. Equities analysts expect that Verona Pharma PLC American Depositary Share will post -1.95 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Verona Pharma PLC American Depositary Share

Hedge funds and other institutional investors have recently made changes to their positions in the company. Blue Trust Inc. acquired a new position in Verona Pharma PLC American Depositary Share in the 3rd quarter valued at $38,000. Geneos Wealth Management Inc. grew its position in shares of Verona Pharma PLC American Depositary Share by 44.2% in the first quarter. Geneos Wealth Management Inc. now owns 630 shares of the company’s stock valued at $40,000 after purchasing an additional 193 shares during the last quarter. Acadian Asset Management LLC bought a new position in shares of Verona Pharma PLC American Depositary Share in the first quarter worth about $48,000. IFP Advisors Inc acquired a new position in shares of Verona Pharma PLC American Depositary Share during the 2nd quarter worth about $52,000. Finally, NewEdge Advisors LLC bought a new stake in Verona Pharma PLC American Depositary Share during the 1st quarter valued at approximately $58,000. 85.88% of the stock is owned by hedge funds and other institutional investors.

Verona Pharma PLC American Depositary Share Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.